A citation-based method for searching scientific literature

Emily K Osterweil, Shih-Chieh Chuang, Alexander A Chubykin, Michael Sidorov, Riccardo Bianchi, Robert K S Wong, Mark F Bear. Neuron 2013
Times Cited: 155







List of co-cited articles
1332 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



The mGluR theory of fragile X mental retardation.
Mark F Bear, Kimberly M Huber, Stephen T Warren. Trends Neurosci 2004
38

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.
Aubin Michalon, Michael Sidorov, Theresa M Ballard, Laurence Ozmen, Will Spooren, Joseph G Wettstein, Georg Jaeschke, Mark F Bear, Lothar Lindemann. Neuron 2012
348
34

Correction of fragile X syndrome in mice.
Gül Dölen, Emily Osterweil, B S Shankaranarayana Rao, Gordon B Smith, Benjamin D Auerbach, Sumantra Chattarji, Mark F Bear. Neuron 2007
689
34

Altered synaptic plasticity in a mouse model of fragile X mental retardation.
Kimberly M Huber, Sean M Gallagher, Stephen T Warren, Mark F Bear. Proc Natl Acad Sci U S A 2002
963
32

Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.
Christina Henderson, Lasani Wijetunge, Mika Nakamoto Kinoshita, Matthew Shumway, Rebecca S Hammond, Friso R Postma, Christopher Brynczka, Roger Rush, Alexia Thomas, Richard Paylor,[...]. Sci Transl Med 2012
175
30

FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism.
Jennifer C Darnell, Sarah J Van Driesche, Chaolin Zhang, Ka Ying Sharon Hung, Aldo Mele, Claire E Fraser, Elizabeth F Stone, Cynthia Chen, John J Fak, Sung Wook Chi,[...]. Cell 2011
30

Metformin ameliorates core deficits in a mouse model of fragile X syndrome.
Ilse Gantois, Arkady Khoutorsky, Jelena Popic, Argel Aguilar-Valles, Erika Freemantle, Ruifeng Cao, Vijendra Sharma, Tine Pooters, Anmol Nagpal, Agnieszka Skalecka,[...]. Nat Med 2017
105
29

Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study.
Artuela Çaku, David Pellerin, Paméla Bouvier, Emilie Riou, Francois Corbin. Am J Med Genet A 2014
45
62

Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice.
Aditi Bhattacharya, Hanoch Kaphzan, Amanda C Alvarez-Dieppa, Jaclyn P Murphy, Philippe Pierre, Eric Klann. Neuron 2012
209
27

Dysregulation of mTOR signaling in fragile X syndrome.
Ali Sharma, Charles A Hoeffer, Yukihiro Takayasu, Takahiro Miyawaki, Sean M McBride, Eric Klann, R Suzanne Zukin. J Neurosci 2010
397
22

Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse.
Mei Qin, Julia Kang, Thomas V Burlin, Chunhui Jiang, Carolyn Beebe Smith. J Neurosci 2005
169
22

A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome.
Mary Jacena S Leigh, Danh V Nguyen, Yi Mu, Tri I Winarni, Andrea Schneider, Tasleem Chechi, Jonathan Polussa, Paul Doucet, Flora Tassone, Susan M Rivera,[...]. J Dev Behav Pediatr 2013
155
21

Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.
T V Bilousova, L Dansie, M Ngo, J Aye, J R Charles, D W Ethell, I M Ethell. J Med Genet 2009
317
21

Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.
Elizabeth M Berry-Kravis, David Hessl, Barbara Rathmell, Peter Zarevics, Maryann Cherubini, Karen Walton-Bowen, Yi Mu, Danh V Nguyen, Joseph Gonzalez-Heydrich, Paul P Wang,[...]. Sci Transl Med 2012
226
20

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.
Elizabeth Berry-Kravis, Vincent Des Portes, Randi Hagerman, Sébastien Jacquemont, Perrine Charles, Jeannie Visootsak, Marc Brinkman, Karin Rerat, Barbara Koumaras, Liansheng Zhu,[...]. Sci Transl Med 2016
152
20

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.
Q J Yan, M Rammal, M Tranfaglia, R P Bauchwitz. Neuropharmacology 2005
392
19

Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome.
Christina Gross, Chia-Wei Chang, Seth M Kelly, Aditi Bhattacharya, Sean M J McBride, Scott W Danielson, Michael Q Jiang, Chi Bun Chan, Keqiang Ye, Jay R Gibson,[...]. Cell Rep 2015
66
27

Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model.
Harpreet Sidhu, Lorraine E Dansie, Peter W Hickmott, Douglas W Ethell, Iryna M Ethell. J Neurosci 2014
107
18

Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.
A J Verkerk, M Pieretti, J S Sutcliffe, Y H Fu, D P Kuhl, A Pizzuti, O Reiner, S Richards, M F Victoria, F P Zhang. Cell 1991
18

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.
Elizabeth M Berry-Kravis, Lothar Lindemann, Aia E Jønch, George Apostol, Mark F Bear, Randall L Carpenter, Jacqueline N Crawley, Aurore Curie, Vincent Des Portes, Farah Hossain,[...]. Nat Rev Drug Discov 2018
154
18

Altered Neuronal and Circuit Excitability in Fragile X Syndrome.
Anis Contractor, Vitaly A Klyachko, Carlos Portera-Cailliau. Neuron 2015
202
17

Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes.
Christos G Gkogkas, Arkady Khoutorsky, Ruifeng Cao, Seyed Mehdi Jafarnejad, Masha Prager-Khoutorsky, Nikolaos Giannakas, Archontia Kaminari, Apostolia Fragkouli, Karim Nader, Theodore J Price,[...]. Cell Rep 2014
120
17

Dysregulation and restoration of translational homeostasis in fragile X syndrome.
Joel D Richter, Gary J Bassell, Eric Klann. Nat Rev Neurosci 2015
157
17

The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.
Weidong Li, Yijun Cui, Steven A Kushner, Robert A M Brown, J David Jentsch, Paul W Frankland, Tyrone D Cannon, Alcino J Silva. Curr Biol 2005
273
16

Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression.
Lingfei Hou, Marcia D Antion, Daoying Hu, Corinne M Spencer, Richard Paylor, Eric Klann. Neuron 2006
348
16

Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome.
Xinglong Wang, Mike Snape, Eric Klann, Jeremy G Stone, Avneet Singh, Robert B Petersen, Rudy J Castellani, Gemma Casadesus, Mark A Smith, Xiongwei Zhu. J Neurochem 2012
52
30

Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome.
Christina Gross, Mika Nakamoto, Xiaodi Yao, Chi-Bun Chan, So Y Yim, Keqiang Ye, Stephen T Warren, Gary J Bassell. J Neurosci 2010
185
15


Selective role of the catalytic PI3K subunit p110β in impaired higher order cognition in fragile X syndrome.
Christina Gross, Nisha Raj, Gemma Molinaro, Amanda G Allen, Alonzo J Whyte, Jay R Gibson, Kimberly M Huber, Shannon L Gourley, Gary J Bassell. Cell Rep 2015
55
27

The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP.
Ilaria Napoli, Valentina Mercaldo, Pietro Pilo Boyl, Boris Eleuteri, Francesca Zalfa, Silvia De Rubeis, Daniele Di Marino, Evita Mohr, Marzia Massimi, Mattia Falconi,[...]. Cell 2008
401
15

Open-label add-on treatment trial of minocycline in fragile X syndrome.
Carlo Paribello, Leeping Tao, Anthony Folino, Elizabeth Berry-Kravis, Michael Tranfaglia, Iryna M Ethell, Douglas W Ethell. BMC Neurol 2010
155
15

The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome.
Sien Braat, Charlotte D'Hulst, Inge Heulens, Silvia De Rubeis, Edwin Mientjes, David L Nelson, Rob Willemsen, Claudia Bagni, Debby Van Dam, Peter P De Deyn,[...]. Cell Cycle 2015
50
30

Arbaclofen in fragile X syndrome: results of phase 3 trials.
Elizabeth Berry-Kravis, Randi Hagerman, Jeannie Visootsak, Dejan Budimirovic, Walter E Kaufmann, Maryann Cherubini, Peter Zarevics, Karen Walton-Bowen, Paul Wang, Mark F Bear,[...]. J Neurodev Disord 2017
90
16

High MMP-9 activity levels in fragile X syndrome are lowered by minocycline.
Magdalena Dziembowska, Dalyir I Pretto, Aleksandra Janusz, Leszek Kaczmarek, Mary Jacena Leigh, Nielsen Gabriel, Blythe Durbin-Johnson, Randi J Hagerman, Flora Tassone. Am J Med Genet A 2013
109
15

Targeting the endocannabinoid system in the treatment of fragile X syndrome.
Arnau Busquets-Garcia, Maria Gomis-González, Thomas Guegan, Carmen Agustín-Pavón, Antoni Pastor, Susana Mato, Alberto Pérez-Samartín, Carlos Matute, Rafael de la Torre, Mara Dierssen,[...]. Nat Med 2013
143
14

The pathophysiology of fragile X (and what it teaches us about synapses).
Asha L Bhakar, Gül Dölen, Mark F Bear. Annu Rev Neurosci 2012
259
14

Conserved hippocampal cellular pathophysiology but distinct behavioural deficits in a new rat model of FXS.
Sally M Till, Antonis Asiminas, Adam D Jackson, Danai Katsanevaki, Stephanie A Barnes, Emily K Osterweil, Mark F Bear, Sumantra Chattarji, Emma R Wood, David J A Wyllie,[...]. Hum Mol Genet 2015
57
24

Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome.
V Brown, P Jin, S Ceman, J C Darnell, W T O'Donnell, S A Tenenbaum, X Jin, Y Feng, K D Wilkinson, J D Keene,[...]. Cell 2001
850
14

Advances in the treatment of fragile X syndrome.
Randi J Hagerman, Elizabeth Berry-Kravis, Walter E Kaufmann, Michele Y Ono, Nicole Tartaglia, Ave Lachiewicz, Rebecca Kronk, Carol Delahunty, David Hessl, Jeannie Visootsak,[...]. Pediatrics 2009
360
14


FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels.
Pan-Yue Deng, Ziv Rotman, Jay A Blundon, Yongcheol Cho, Jianmin Cui, Valeria Cavalli, Stanislav S Zakharenko, Vitaly A Klyachko. Neuron 2013
212
13

Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome.
Jose Luis Olmos-Serrano, Scott M Paluszkiewicz, Brandon S Martin, Walter E Kaufmann, Joshua G Corbin, Molly M Huntsman. J Neurosci 2010
218
13

Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.
Craig A Erickson, Logan K Wink, Balmiki Ray, Maureen C Early, Elizabeth Stiegelmeyer, Lauren Mathieu-Frasier, Vanessa Patrick, Debomoy K Lahiri, Christopher J McDougle. Psychopharmacology (Berl) 2013
67
19

Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome.
Jennifer A Ronesi, Katie A Collins, Seth A Hays, Nien-Pei Tsai, Weirui Guo, Shari G Birnbaum, Jia-Hua Hu, Paul F Worley, Jay R Gibson, Kimberly M Huber. Nat Neurosci 2012
178
13

Metformin as targeted treatment in fragile X syndrome.
A B C Dy, F Tassone, M Eldeeb, M J Salcedo-Arellano, N Tartaglia, R Hagerman. Clin Genet 2018
40
32

Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet's signaling cascades as new outcome measures in clinical trials.
David Pellerin, Artuela Çaku, Mathieu Fradet, Paméla Bouvier, Jean Dubé, François Corbin. Biomarkers 2016
25
52

Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology.
Tsuyoshi Udagawa, Natalie G Farny, Mira Jakovcevski, Hanoch Kaphzan, Juan Marcos Alarcon, Shobha Anilkumar, Maria Ivshina, Jessica A Hurt, Kentaro Nagaoka, Vijayalaxmi C Nalavadi,[...]. Nat Med 2013
83
14

Absence of expression of the FMR-1 gene in fragile X syndrome.
M Pieretti, F P Zhang, Y H Fu, S T Warren, B A Oostra, C T Caskey, D L Nelson. Cell 1991
12

Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome.
Elizabeth Berry-Kravis, Allison Sumis, Crystal Hervey, Michael Nelson, Stephen W Porges, Ning Weng, Ivan Jeanne Weiler, William T Greenough. J Dev Behav Pediatr 2008
161
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.